[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR121483A1 - Hidrato cristalino de un compuesto inhibidor de jak - Google Patents

Hidrato cristalino de un compuesto inhibidor de jak

Info

Publication number
AR121483A1
AR121483A1 ARP210100530A ARP210100530A AR121483A1 AR 121483 A1 AR121483 A1 AR 121483A1 AR P210100530 A ARP210100530 A AR P210100530A AR P210100530 A ARP210100530 A AR P210100530A AR 121483 A1 AR121483 A1 AR 121483A1
Authority
AR
Argentina
Prior art keywords
crystalline hydrate
inhibitor compound
jak inhibitor
hydrate
crystalline
Prior art date
Application number
ARP210100530A
Other languages
English (en)
Inventor
Gene Timothy Fass
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of AR121483A1 publication Critical patent/AR121483A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporciona aquí un hidrato cristalino del compuesto de fórmula (1). También se proporcionan en el presente documento composiciones farmacéuticas que comprenden dicho hidrato cristalino, métodos de uso de dicho hidrato cristalino para tratar enfermedades respiratorias y procesos útiles para preparar dicho hidrato cristalino.
ARP210100530A 2020-03-02 2021-03-01 Hidrato cristalino de un compuesto inhibidor de jak AR121483A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062983931P 2020-03-02 2020-03-02

Publications (1)

Publication Number Publication Date
AR121483A1 true AR121483A1 (es) 2022-06-08

Family

ID=75143791

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100530A AR121483A1 (es) 2020-03-02 2021-03-01 Hidrato cristalino de un compuesto inhibidor de jak

Country Status (16)

Country Link
US (2) US11702415B2 (es)
EP (1) EP4114836A1 (es)
JP (1) JP2023516640A (es)
KR (1) KR20220149585A (es)
CN (1) CN115190878B (es)
AR (1) AR121483A1 (es)
AU (1) AU2021232100A1 (es)
BR (1) BR112022017398A2 (es)
CA (1) CA3172338A1 (es)
CL (1) CL2022002368A1 (es)
CO (1) CO2022012476A2 (es)
IL (1) IL295613A (es)
MX (1) MX2022010795A (es)
TW (1) TW202144343A (es)
WO (1) WO2021178991A1 (es)
ZA (1) ZA202209617B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021002521A (es) * 2018-09-04 2021-04-28 Theravance Biopharma R&D Ip Llc Dimetilaminoazetidinaminas como inhibidores de jak.
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
WO2023230236A1 (en) * 2022-05-26 2023-11-30 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof
CN116785290B (zh) * 2023-02-01 2024-02-13 银谷制药有限责任公司 苯环喹溴铵及其异构体在制备眼用制剂中的应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
EP2414340A1 (en) 2009-04-03 2012-02-08 Dainippon Sumitomo Pharma Co., Ltd. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
EP2515655B1 (en) 2009-12-21 2015-08-05 Samumed, LLC 1h-pyrazolo[3,4-beta]pyridines and therapeutic uses thereof
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
TN2016000227A1 (fr) 2013-12-05 2017-10-06 Pfizer Pyrrolo[2,3-d]pyrimidinyle, pyrrolo[2,3-b]pyrazinyle et pyrollo[2,3-d]pyridinyle acrylamides.
TN2016000503A1 (en) 2014-05-14 2018-04-04 Pfizer Pyrazolopyridines and pyrazolopyrimidines
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
CA3037248A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
WO2017077283A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
UA123633C2 (uk) 2015-11-03 2021-05-05 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі Сполуки інгібітору jak-кінази для лікування респіраторного захворювання
EP3592743A1 (en) 2017-03-09 2020-01-15 Theravance Biopharma R&D IP, LLC Fused imidazo-piperidine jak inhibitors
US20180258546A1 (en) 2017-03-09 2018-09-13 Lam Research Corporation Electroplating apparatus and methods utilizing independent control of impinging electrolyte
MX2019012950A (es) 2017-05-01 2019-12-16 Theravance Biopharma R&D Ip Llc Metodos de tratamiento mediante el uso de un compuesto inhibidor de jak.
WO2018204236A1 (en) * 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Crystalline forms of a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
AR116114A1 (es) 2018-09-04 2021-03-31 Theravance Biopharma R&D Ip Llc Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak
MX2021002521A (es) 2018-09-04 2021-04-28 Theravance Biopharma R&D Ip Llc Dimetilaminoazetidinaminas como inhibidores de jak.
KR20210056382A (ko) 2018-09-04 2021-05-18 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제 및 이의 중간체를 제조하는 방법
MX2021004582A (es) 2018-10-29 2021-06-15 Theravance Biopharma R&D Ip Llc Compuesto 2-azabiciclo hexano inhibidor de jak.
CN111606908B (zh) 2019-02-25 2021-08-24 河南迈英诺医药科技有限公司 Jak抑制剂化合物及其用途
KR20210137087A (ko) 2019-03-05 2021-11-17 인사이트 코포레이션 만성 폐 동종이식 기능장애의 치료를 위한 jak1 경로 억제제
CN112279848A (zh) 2019-07-25 2021-01-29 四川海思科制药有限公司 一种泛JAKs抑制剂及其用途
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
TW202207921A (zh) 2020-05-08 2022-03-01 美商施萬生物製藥研發Ｉｐ有限責任公司 以二甲基胺基吖呾醯胺化合物治療受冠狀病毒感染的患者之方法
WO2022271604A1 (en) 2021-06-21 2022-12-29 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l

Also Published As

Publication number Publication date
BR112022017398A2 (pt) 2022-10-18
TW202144343A (zh) 2021-12-01
KR20220149585A (ko) 2022-11-08
US20240025897A1 (en) 2024-01-25
US12122773B2 (en) 2024-10-22
IL295613A (en) 2022-10-01
US11702415B2 (en) 2023-07-18
CO2022012476A2 (es) 2022-09-20
MX2022010795A (es) 2022-11-30
US20210269437A1 (en) 2021-09-02
EP4114836A1 (en) 2023-01-11
CA3172338A1 (en) 2021-09-10
JP2023516640A (ja) 2023-04-20
AU2021232100A1 (en) 2022-10-20
CN115190878B (zh) 2024-10-29
WO2021178991A1 (en) 2021-09-10
CN115190878A (zh) 2022-10-14
CL2022002368A1 (es) 2023-04-21
ZA202209617B (en) 2023-04-26

Similar Documents

Publication Publication Date Title
AR121483A1 (es) Hidrato cristalino de un compuesto inhibidor de jak
CL2022001739A1 (es) Compuestos tricíclicos sustituidos
CO2022008997A2 (es) Compuestos tricíclicos sustituidos
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
AR111495A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
ZA202007566B (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
DOP2021000077A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
CL2024000067A1 (es) Compuestos antivirales
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
CL2021000844A1 (es) Compuestos de indolinona para uso como inhibidores de map4k1
BR112023012947A2 (pt) Inibidores de lrrk2
CL2024000373A1 (es) Compuesto inductor de la degradación de plk1 novedoso
ECSP23054131A (es) Cocristal de un inhibidor de cdk
CL2022002975A1 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
CO2021011023A2 (es) Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos
AR128109A1 (es) Spiros y análogos relacionados para inhibir yap / taz-tead
BR112023015721A2 (pt) Derivados tricíclicos úteis como inibidores de parp7
BR112022001164A2 (pt) Composto, uso de um composto, método para o tratamento ou profilaxia de doenças, composto para uso e composição farmacêutica
ECSP23075535A (es) Compuestos cíclicos y métodos de uso
ECSP24007193A (es) Compuestos pirimidínicos para usar como inhibidores de map4k1
CL2023003979A1 (es) Inhibidores de las transglutaminasas
CL2023003921A1 (es) Inhibidores de transglutaminasas
ECSP24007534A (es) Inhibidores de transglutaminasas
MX2023000727A (es) 4-furanamidas y procedimiento para su preparacion.

Legal Events

Date Code Title Description
FB Suspension of granting procedure